WaveCloud
WaveCloud Raises $500M Series E to Transform Biotech
Quick Facts
WaveCloud Raises $500M Series E in Latest Funding Round
WaveCloud has successfully closed a $500M Series E funding round, marking a significant milestone in the company's growth trajectory. The round was led by NEA, with participation from Andreessen Horowitz.
Company Overview
Founded in 2020 and headquartered in Atlanta, GA, WaveCloud has established itself in the Biotech space. Leading machine learning platform automating enterprise workflows with advanced AI models
With a current valuation of $10B, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $500M Series E
- Valuation: $10B
- Lead Investor: NEA
Future Outlook
As WaveCloud moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza